3,5-T2-an Endogenous Thyroid Hormone Metabolite as Promising Lead Substance in Anti-Steatotic Drug Development?
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic, preclinical, and early clinical literature without systematic review methodology.
PubMed 35888706 · doi:10.3390/metabo12070582
What was done
This narrative review examined preclinical rodent models and early human trial literature on the endogenous thyroid hormone metabolite 3,5-diiodothyronine (3,5-T2) and its synthetic analogue TRC150094, focusing on their mechanisms of action, mitochondrial targets, and effects on hepatic lipid and glucose metabolism.
What was found
The abstract reports no quantitative data. Preclinical and early human trials showed antisteatotic hepatic actions via canonical and non-canonical mitochondrial mechanisms. However, compounds demonstrated species- and dose-dependent efficacy, unwanted thyromimetic cardiac effects, and suppression of the hypothalamus-pituitary-thyroid axis. The authors found no convincing evidence supporting clinical use of 3,5-T2 or its analogues for obesity or related metabolic disorders.
Why it matters
While thyroid hormone metabolites provide mechanistic insights into liver-specific lipid clearance, safety liabilities on the heart and endocrine axis remain substantial barriers to drug development.
Limits
The review relies on narrative synthesis without systematic search criteria, meta-analysis, or pooled quantitative results. Most discussed evidence derives from animal models, and safety concerns limit applicability to humans.
Cited by
- supports Natural desiccated thyroid formulations contain a blend of T4, T3, and T2.